Abstract

There is an ongoing debate on the benefit of obtaining repeat blood cultures for Gram-negative bacterial bloodstream infections (GNBSI). However, there is a scarcity of data concerning patients with hematologic malignancies. We sought to assess the utility of obtaining follow-up blood cultures (FUBC) in GNBSI among patients with hematologic malignancies. A retrospective chart review was conducted to identify all admitted patients with hematologic malignancies with GNBSI from 2018 to 2021 at a tertiary academic medical center. We collected demographics, cancer history and treatment, microbiology and antibiotic use, and clinical course. Descriptive statistics were used. A total of 46 episodes of GNBSI among 38 patients were included. The median age was 61.5 years, 63% were male, 50% were White, and 16% were Latinx. Most patients had acute myeloid leukemia (60%), and the most common chemotherapy regimen was cytarabine or nelarabine regimens (35%).Klebsiella pneumoniaewas responsible for 37% of the GNBSI cases, in the setting of long-term central venous catheter use (65%) and gastrointestinal sources (50%). FUBCs were collected among almost all patients (98%). Only three cases (7%) had positive FUBC: one had a delay in appropriate therapy, another had a lack of source control, and the last case did not have a source identified. Most patients were treated with beta-lactams (52%) with duration 8-14 days (52%). 22% were admitted to ICU and 9% died during their hospitalization. We found a few cases of positive FUBC. Routine FUBC may not be appropriate for all GNBSI patients with hematological malignancies, particularly during the current blood culture bottle shortage.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.